Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials
- DOI
- 10.1016/s2213-8587(24)00155-4
- Published
- 2024-08
- Container
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/s2213-8587-24-00155-4,
title = {Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials},
author = {Ellen M Apperloo and Brendon L Neuen and Robert A Fletcher and Niels Jongs and Stefan D Anker and Deepak L Bhatt and Javed Butler and David Z I Cherney and William G Herrington and Silvio E Inzucchi and Meg J Jardine and Chih-Chin Liu and Kenneth W Mahaffey and Darren K McGuire and John J V McMurray and Bruce Neal and Milton Packer and Vlado Perkovic and Marc S Sabatine and Scott D Solomon and Natalie Staplin and Michael Szarek and Muthiah Vaduganathan and Christoph Wanner and David C Wheeler and Stephen D Wiviott and Faiez Zannad and Hiddo J L Heerspink},
year = {2024},
journal = {The Lancet Diabetes \& Endocrinology},
doi = {10.1016/s2213-8587(24)00155-4},
url = {https://doi.org/10.1016/s2213-8587(24)00155-4}
}RIS
TY - JOUR TI - Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials AU - Ellen M Apperloo AU - Brendon L Neuen AU - Robert A Fletcher AU - Niels Jongs AU - Stefan D Anker AU - Deepak L Bhatt AU - Javed Butler AU - David Z I Cherney AU - William G Herrington AU - Silvio E Inzucchi AU - Meg J Jardine AU - Chih-Chin Liu AU - Kenneth W Mahaffey AU - Darren K McGuire AU - John J V McMurray AU - Bruce Neal AU - Milton Packer AU - Vlado Perkovic AU - Marc S Sabatine AU - Scott D Solomon AU - Natalie Staplin AU - Michael Szarek AU - Muthiah Vaduganathan AU - Christoph Wanner AU - David C Wheeler AU - Stephen D Wiviott AU - Faiez Zannad AU - Hiddo J L Heerspink PY - 2024 JO - The Lancet Diabetes & Endocrinology DO - 10.1016/s2213-8587(24)00155-4 UR - https://doi.org/10.1016/s2213-8587(24)00155-4 ER -
APA
Apperloo, E. M., Neuen, B. L., Fletcher, R. A., Jongs, N., Anker, S. D., Bhatt, D. L., Butler, J., Cherney, D. Z. I., Herrington, W. G., Inzucchi, S. E., Jardine, M. J., Liu, C., Mahaffey, K. W., McGuire, D. K., McMurray, J. J. V., Neal, B., Packer, M., Perkovic, V., Sabatine, M. S., Solomon, S. D., Staplin, N., Szarek, M., Vaduganathan, M., Wanner, C., Wheeler, D. C., Wiviott, S. D., Zannad, F., & Heerspink, H. J. L. (2024). Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(24)00155-4
Source records
- crossref · retrieved 2026-09-26T19:19:14.067Z